Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCTOPC1 for spinal cord injury (DOSED)
NCT06841770Phase 1Recruiting
- Sponsor
- Lineage Cell Therapeutics
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPC1 in spinal cord injury (SCI), sponsored by Lineage Cell Therapeutics. Primary endpoint: Frequency and Severity of Adverse Events Related to the Delivery Device or Injection Procedure at 30 days. Started Jun 2025; status: recruiting.
02
Drugs
OPC1
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06841770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841770.